Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 10;40(1):3-5.
doi: 10.1016/j.ccell.2021.11.006. Epub 2021 Nov 16.

Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer

Lauren C Shapiro  1 , Astha Thakkar  1 , Sean T Campbell  2 , Stefanie K Forest  2 , Kith Pradhan  1 , Jesus D Gonzalez-Lugo  1 , Ryann Quinn  1 , Tushar D Bhagat  1 , Gaurav S Choudhary  1 , Margaret McCort  3 , R Alejandro Sica  1 , Mendel Goldfinger  1 , Swati Goel  1 , Jesus D Anampa  1 , David Levitz  1 , Ariel Fromowitz  1 , Akash Pradip Shah  1 , Charlotte Sklow  1 , Gregory Alfieri  1 , Andrew Racine  4 , Lucia Wolgast  2 , Lee Greenberger  5 , Amit Verma  6 , Balazs Halmos  7
Affiliations

Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer

Lauren C Shapiro et al. Cancer Cell. .

Abstract

Anti-COVID-19 immunity dynamics were assessed in patients with cancer in a prospective clinical trial. Waning of immunity was detected 4-6 months post-vaccination with significant increases in anti-spike IgG titers after booster dosing, and 56% of seronegative patients seroconverted post-booster vaccination. Prior anti-CD20/BTK inhibitor therapy was associated with reduced vaccine efficacy.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests R.A.S. serves as a consultant with Morphosys and Miragen and is on the faculty at Physicians’ Education Research. A.V. has received research funding from GlaxoSmithKline, BMS, Janssen, Incyte, MedPacto, Celgene, Novartis, Curis, Prelude, and Eli Lilly and Company; has received compensation as a scientific advisor to Novartis, Stelexis Therapeutics, Acceleron Pharma, and Celgene; and has equity ownership in Stelexis Therapeutics. All other authors declare no competing interests.

References

    1. Addeo A., Shah P.K., Bordry N., Hudson R.D., Albracht B., Di Marco M., Kaklamani V., Dietrich P.Y., Taylor B.S., Simand P.F., et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 2021;39:1091–1098.e2. - PMC - PubMed
    1. Barda N., Dagan N., Cohen C., Hernán M.A., Lipsitch M., Kohane I.S., Reis B.Y., Balicer R.D. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021 doi: 10.1016/S0140-6736(21)02249-2. S0140-6736(21)02249-2. - DOI - PMC - PubMed
    1. Greenberger L.M., Saltzman L.A., Senefeld J.W., Johnson P.W., DeGennaro L.J., Nichols G.L. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021;39:1031–1033. - PMC - PubMed
    1. Greenberger L.M., Saltzman L.A., Senefeld J.W., Johnson P.W., DeGennaro L.J., Nichols G.L. Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies. Cancer Cell. 2021;39:1297–1299. - PMC - PubMed
    1. Hall V.G., Ferreira V.H., Ku T., Ierullo M., Majchrzak-Kita B., Chaparro C., Selzner N., Schiff J., McDonald M., Tomlinson G., et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N. Engl. J. Med. 2021;385:1244–1246. - PMC - PubMed

Publication types

MeSH terms